Quality of Care Standards in Inflammatory Bowel Diseases
Quality of Care Standards in Inflammatory Bowel Diseases: a European Crohn’s and Colitis Organisation [ECCO] Position Paper
February, 2020
Empowerment
The Future of Biosimilars
The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory Diseases
February, 2020
The Socioeconomic Impact of Living With Ulcerative Colitis
43 The Socioeconomic Impact of Living With Ulcerative Colitis: A Burden of Illness Study
October, 2019
The living with Ulcerative Colitis (UC), identifying the socioeconomic burden in Europe (LUCID) study was a descriptive, retrospective, cross-sectional, European, multi-site, bottom-up Burden of Illness research study carried out by HCD Economics and the University of Chester in partnership with Crohn's and Colitis UK.
The Impact of Ulcerative Colitis on Quality of Life and Productivity Across Europe
744 The Impact of Ulcerative Colitis on Quality of Life and Productivity Across Europe: A Burden of Illness Study
October, 2019
Changes in inflammatory bowel disease patients’ perspectives on biosimilars
Changes in inflammatory bowel disease patients’ perspectives on biosimilars: A follow-up survey
October, 2019
The aim of this survey was to find out whether the perspectives of patients with inflammatory bowel disease concerning biosimilars have changed since the publication of our last survey carried out in 2014–2015.
Innovative medicines - Mapping project
Innovative medicines - EU mapping project
Nurses are Critical in Aiding Patients Transitioning to Biosimilars in Inflammatory Bowel Disease
Nurses are Critical in Aiding Patients Transitioning to Biosimilars in Inflammatory Bowel Disease: Education and Communication Strategies
October, 2018
Survey on couple with IBD and their offspring
IBD and parenthood - Survey on couples with IBD and their offspring
Iron deficiency with or without anaemia in IBD
P328 Patient and physician perspectives on managing iron deficiency with or without anaemia in inflammatory bowel disease: findings from a European online survey
Iron deficiency (ID) and iron deficiency anaemia (IDA) are conditions frequently observed in patients with inflammatory bowel disease (IBD) and require appropriate treatment. This study investigated patient and physician perspectives on the management of these conditions.
Patient Safety: Biologics and Biosimilars
Since about 2015 the issue on biologics and biosimilars has received a lot of attention from the medical, regulatory and patient community. Licensing rights of biological medicines used in the treatment not only of IBD but also other autoimmune modulated diseases are coming to an end and biosimilars medicines are being developed to compete with original biological treatment options. In various countries in the EU and elsewhere biosimilars have already entered the market.